港股異動|心瑋醫療-B大升超15.7% 創近兩年新高 三項產品重磅亮相神經介入舞台
心瑋醫療-B(6609.HK)大升超15.7%,最高觸及39.4港元,創近兩年以來新高。消息面上,近期,東方腦血管病會議(OCIN 2025)與世界神經介入大會(WLNC)首次聯合辦會,心瑋醫療攜國產首款顱內動脈瘤栓塞輔助支架“長城”、首款塗層密網支架“如意”及革命性取栓技術“CATCH級聯”重磅亮相。三者既填補了國產高端器械空白,更以差異化創新切入全球技術競合。另外,今年最新發布的《關於優化全生命週期監管、支持高端醫療器械創新發展的舉措(徵求意見稿)》,明確提出推動國際標準接軌,建立“創新特別審查”綠色通道,全力支持高端醫療器械重大創新。而心瑋醫療作為從事創新型神經介入醫療器械研發的公司,有望受益於政策支持。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.